Project Grant P50CA272391
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$2.2M
Federal Agency
National Cancer Institute
Federal Grant Program
93.397
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
The Johns Hopkins University will provide research services totaling $1,216,646 under a Project Grant award from the Defense Health Agency. The award's stated purpose is to investigate the role of polyamine metabolism in advanced prostate cancer. The grant falls under the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to transform military and public health care. Specifically, the program aims to develop medical solutions for battlefield...
The University of California, San Francisco (UCSF) was awarded a $4,408,316 Project Grant from the National Cancer Institute (NCI) under the Cancer Centers Support Grants (CFDA 93.397) program. The grant, titled "UCSF SPECIALIZED PROGRAMS OF RESEARCH EXCELLENCE (SPORES) IN PROSTATE CANCER", will fund transdisciplinary research aimed at reducing the morbidity and mortality associated with prostate cancer. The key objectives are to: A) investigate molecular drivers of aggressive prostate...
This $1,972,922.00 Project Grant was awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant supports research conducted by The Johns Hopkins University to therapeutically target TREM2-positive tumor-associated macrophages within the tumor microenvironment of lethal prostate cancer, with the goal of reducing health disparities. The project will run from July 1, 2025 to June 30, 2028. As a leading academic research...
This federal Project Grant award for $710,980.00 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research aimed at defining the molecular mechanisms and therapeutic potential of targeting the SPOP ubiquitin signaling pathway in prostate cancer. Key objectives include: Elucidating the role of the SPOP pathway regulator G3BP1 in driving prostate tumorigenesis and evaluating the ability to target this upstream axis. Establishing the...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $271,697 Project Grant to The Johns Hopkins University on Sep 1, 2024. The grant funds research to "TARGET GUT BACTERIAL ANDROGEN PRODUCTION TO REVERSE ABIRATERONE RESISTANCE IN METASTATIC PROSTATE CANCER". This research aims to develop new treatments for metastatic prostate cancer by investigating the role of gut bacteria in androgen production and resistance to certain cancer...
This federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $232,878 to The Johns Hopkins University to explore the role of epitranscriptomics in the evolution of neuroendocrine prostate cancer. The award period runs from June 1, 2025 to May 31, 2027. As a leading research institution, Johns Hopkins University has a strong track record of delivering critical scientific research and...
This $1,473,751 federal Project Grant award, issued on August 15, 2024 by the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420), supports research by The Johns Hopkins University to investigate the influence of the tumor immune microenvironment and microbiome on prostate cancer immunotherapy response in Black men. The 3-year research initiative aims to transform healthcare through innovative and impactful medical research focused...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $545,078 to The Johns Hopkins University from February 1, 2025 to January 31, 2030. The project aims to systematically evaluate the effect of prostate-specific membrane antigen (PSMA)-based radiopharmaceutical therapy (PSMA-RPT) on glutaminolysis, a key metabolic pathway, in experimental models of prostate cancer (PC) and renal cell carcinoma (RCC). The research will assess...
The Johns Hopkins University was awarded a $1,228,125 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will support research titled "PSMA-TARGETED ACTIVATED MYELOID CELLS AS A NOVEL PROSTATE CANCER IMMUNOTHERAPY" from September 2021 through September 2024. The Military Medical Research and Development program aims to transform military and public health through innovative biomedical...
This $683,979 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research conducted by Weill Medical College of Cornell University to define the molecular mechanisms underlying the progression of prostate cancer to treatment-resistant subtypes. The key objectives are to: 1) Determine the propensity of prostate cancers with SPOP mutations to progress to androgen receptor (AR)-indifferent disease, 2) Elucidate how SPOP mutations and...